Michelle Mallitz, MD

In a new review for #JACC, DCRI Fellow Mark Kittipibul and Rob Mentz discuss the benefits of SGLT2i, the associated risk of GU infections, and practice considerations for patients with cardiovascular disease: https://lnkd.in/efaBRkrK #clinicaltrials #clinicalresearch #heartdisease

10

The #NASCI Case of the Month: Desmoplakin Cardiomyopathy Masquerading as Acute Myocarditis has been published in the @IJCVImaging! Read the full case report here: https://buff.ly/3UsR1bX #cardiovascularimaging

11

Clinicians: A new CME from MMWR and Medscape discusses the 2024 Adult immunization schedule. The schedule consolidates and summarizes current Advisory Committee on Immunization Practices (ACIP) recommendations. You can use the 2024 immunization schedules to determine recommended vaccines for your patients. Earn free CE and CME here: https://bit.ly/3yaDsq1

19

1 Comment

In this cohort study of a colorectal cancer screening program, sequential automated and personalized strategies each were linked to substantial increases in screening completion in all demographic groups. https://ja.ma/3Uj1fg0

1

Hepatitis D is a liver disease caused by infection with hepatitis D virus. This JAMA Patient Page describes hepatitis D infection and its risk factors, outcomes of acute and chronic infection, diagnosis, treatment, and prevention. https://ja.ma/3UISomL

12

Hepatitis D is a liver disease caused by infection with hepatitis D virus. This JAMA Patient Page describes hepatitis D infection and its risk factors, outcomes of acute and chronic infection, diagnosis, treatment, and prevention. https://ja.ma/3vWSL4W

82

#InTheNews: Surviving trauma: Here is how UAB is tackling the trauma care gap Zero preventable deaths — that is the shared goal of trauma surgeons across the country, including at the University of Alabama at Birmingham. Trauma is the most common cause of death for patients younger than 45 years of age, according to the Alabama Chapter of the American College of Surgeons. “Our goal of zero preventable deaths drives the mission of trauma professionals at UAB,” said Jeffrey Kerby, M.D., Ph.D., director of the UAB Division of Trauma and Acute Care Surgery. “The key to reaching this goal is to ensure the appropriate level of care is provided during what is known as the ‘golden hour,’ which is the most crucial window of time after traumatic injury.” Beyond the Emergency Department In addition to programs that are focused on patient care at the hospital, the division has programs to support trauma survivors after they leave the hospital. Last year, UAB Hospital in collaboration with the Offender Alumni Association, the Jefferson County Department of Health and the City of Birmingham, launched its hospital-based violence intervention program to support patients who are Jefferson County residents between the ages of 19 and 39 who have survived a non-self-inflicted gunshot injury. While still in the hospital, patients are paired with violence intervention specialists who follow up with them over months, providing connections to social, medical and mental health services and monitoring survivors’ progress over time. The objectives of the program include reducing subsequent acts of violence involving the clients, improving client health outcomes, and enhancing client educational attainment, employability and employment status. https://lnkd.in/efc8iAtj #HVIPs #ViolencePrevention

3

Houston, we have liftoff!   The ASCO embargo has lifted on the EpicentRx oral #ASCO24 presentation in Chicago about lead therapy, AdAPT-001.   The presenter is Dr. Anthony Conley, sarcoma specialist and lead investigator on the AdAPT-001 clinical trial from the MD Anderson Cancer Center in Houston, Texas.   This presentation, which takes place from 1:30-1:42 central time in Hall D2 at McCormick Place on June 3rd, 2024, is entitled, “Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.”   It is simultaneously broadcast to ASCO online meeting attendees.   One small step up to the ASCO podium will hopefully translate to one giant step for cancer immunotherapy as Dr. Conley shares the very promising, and possibly (fingers crossed 🤞) practice-changing, results with AdAPT-001 + a checkpoint inhibitor in hard-to-treat, immune refractory cancers.

18

Can we restore cellular function through mitochondrial transplantation? Dr. Mark Kindy, from U.S. Department of Veterans Affairs JAMES A.HALEY VA HOSPITAL and University of South Florida will develop this topic at #TargetingMitochondria2024. Dr. Kindy's presentation will explore the isolation and characterization of mitochondria, application of mitochondrial transplantation, reversal of cellular dysfunction, and restoration of energy metabolism. His team at the VA, is collaborating with MitoSense, Inc. supporter of the congress, on this topic. Join us to know more about mitochondrial transplantation! 📆 October 29-31 📍 DoubleTree by Hilton Berlin Ku'damm 🌐 https://wms-site.com/. #WorldMitochondriaSociety #TargetingMitochondria #mitochondria #mitochondriaresearch #mitochondrialtransplantation #metabolism

49

Most viewed in the last 7 days from JAMA Pediatrics: This JAMA Pediatrics Patient Page describes peanut allergy guidelines and the importance of giving peanut protein to young children to prevent development of an allergy. https://ja.ma/4dQUKJh

7

This cohort study describes the clinical features, patient characteristics, and treatment of anti-melanoma differentiation–associated gene 5 (MDA5) dermatomyositis. https://ja.ma/3vMU4n9

10

Dr. Doug Fowler and Dr. Sumaiya Iqbal reflect on the 2024 Mutational Scanning Symposium and offer suggestions for the 2025 event (Brotman Baty Institute Q&A out today!) Question: Did the symposium meet – or exceed – your expectations? Why? Dr. Iqbal: "Yes; it surely did! I recognized a nice balance in the number of talks focusing on non-coding and protein-coding MAVEs. A mix of computationally and experimentally focused works were also noticeable, and also talks diving deep into specific genes and diseases as well as the development and applications of large-scale resources such as ClinGen, MAVEdb and Genomics 2 Proteins portal." Dr. Fowler: "The symposium definitely exceeded my expectations. We had a great diversity of talks. This was the seventh annual symposium and it has become clear that the mutational scanning space has left its infancy and youth, and is emerging into adulthood. There now are all these amazing and mature applications of the technology and compelling stories in very different topic areas. This is reflective of the technology maturing to the point where people are now using technology to solve complex biological problems." Read the full piece on the BBI website! https://lnkd.in/g2TfDSft

13

Most viewed in the last 7 days from JAMA Oncology: This review assesses current evidence and emerging treatment strategies for improved survival among patients with metastatic hormone-sensitive prostate cancer and offers recommendations for clinical practice application. https://ja.ma/3K6lec1

30

Viewpoint discusses the ethics of AI–generated compassion in cancer care and outlines 4 main points of concern. https://ja.ma/4dqcgDK

10

2 Comments

How do we develop more effective and personalized treatments for Parkinson’s disease (PD)? In a recent A Closer Look blog, we interviewed Dr. Abdulmunaim Eid, a recipient of a 2023-2024 APDA Post-doctoral fellowship, who ​​is hoping to do just that by investigating three clinical subtypes of PD and understanding their biological basis. To learn more about Dr. Eid and his research at https://lnkd.in/eac3nTYh #APDA #PDResearch #Parkinsons

3

UF Health clinician-scientist Bently Doonan, M.D., was interviewed for an article in Florida Weekly that delves into the treatment and prevention of skin cancer. Doonan, an assistant professor in the division of hematology & oncology in the University of Florida College of Medicine, researches melanoma, immunotherapy development and design, brain metastases, and identification of microenvironment targets to induce an immunogenic response in advanced metastatic disease. He discusses how immunotherapy works and ways to protect your skin. Check out the article: https://bit.ly/3Vc3TUl #UFHealthCancerCenter #CancerResearch #SkinCancer #SkinCancerAwareness

10